International Journal of Radiation Research

en Altered expression of lncRNAs DANCR, MIR4435-2HG, and HULC following radiotherapy and their association with radioresistance in prostate cancer Radiation Biology Radiation Biology <div style="text-align: justify;">Background: Radioresistance in prostate cancer (PCa) patients is a challenge that has necessitated identifying standard markers to predict patients’ response to radiotherapy (RT). This study was designed to explore the potential of DANCR and MIR4435-2HG, related to the transforming growth factor-beta (TGF-β) pathway, as well as HULC, whose role in radioresistance has been previously examined, in predicting radiation response in PCa patients. Materials and Methods: Plasma samples were collected from 30 healthy men and 30 PCa patients. RT-qPCR was conducted to detect DANCR, MIR4435-2HG, HULC, and mir-542, mir-424, and mir-372 expressions. Expression levels of TGF-β and TGF-β1 were determined using the enzyme-linked immunosorbent assay (ELISA) and western blot assay. Patients were followed for 11–14 months after RT, and their prostate-specific antigen (PSA) was recorded at 3 and 6 months. Results: Examination of MIR4435-2HG, DANCR, and HULC in plasma samples showed that in radioresistant patients, MIR4435-2HG (0.04 ± 1.47), DANCR (0.08 ± 1.84), and HULC (0.10 ± 1.51) were significantly increased, while mir-424 (0.07 ± 0.49), mir-372 (0.15 ± 0.31), and mir-542 (0.06 ± 0.62) were decreased. Worse pathological features were significantly associated with higher lncRNA expressions. Elevated TGF-β levels were detected in plasma samples from patients who received RT. Conclusion: The significant increase of DANCR, MIR4435-2HG, and HULC in plasma samples of radiation-resistant patients suggests a potential link to radioresistance in PCa. These biomarkers hold promise for personalized medicine, offering new avenues for improving patient management and treatment outcomes.</div> Prostate cancer, radiotherapy, radiation resistance, biomarkers, non-coding RNA. 381 389 http://ijrr.com/browse.php?a_code=A-10-1-1507&slc_lang=en&sid=1 S.M. Taheri 7900319475328460033461 7900319475328460033461 No Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran A. Neshastehriz Neshastehriz@yahoo.com 7900319475328460033462 7900319475328460033462 Yes Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran Z. Hormozi-Moghadam hormozimoghadam.z@iums.ac.ir 7900319475328460033463 7900319475328460033463 No Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran M. Barati 7900319475328460033464 7900319475328460033464 No Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran B. Mofid 7900319475328460033465 7900319475328460033465 No Department of Clinical Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran M. Tajvidi 7900319475328460033466 7900319475328460033466 No Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan S. Majidi 7900319475328460033467 7900319475328460033467 No Department of Clinical Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Z. Abedi Kichi 7900319475328460033468 7900319475328460033468 No Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran